PSMC2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1478606	0.58	12/20
SCHEMBL607010	0.56	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1477637	0.57	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL608782	0.54	11/20
SCHEMBL609278	0.54	11/20
SCHEMBL607553	0.54	11/20
SCHEMBL605822	0.54	11/20
SCHEMBL606932	0.53	11/20
SCHEMBL1477893	0.53	11/20
SCHEMBL608362	0.53	11/20
SCHEMBL608599	0.53	11/20
SCHEMBL1327441	0.53	11/20
SCHEMBL605129	0.52	11/20
SCHEMBL608009	0.52	11/20
SCHEMBL1478157	0.52	11/20
SCHEMBL609081	0.52	11/20
SCHEMBL606926	0.52	11/20

Clinical trials — most relevant to PSMC2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
Bortezomib in Treating Patients With Mantle Cell Lymphoma	PHASE2	COMPLETED
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer	PHASE2	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma	PHASE1	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level	nan	ENROLLING_BY_INVITATION
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMC2 binder may also engage these)

Protein	Name	Similarity
Q4R4R0	—	1.000	Q4R4R0 →
Q63347	—	1.000	Q63347 →
P46471	—	1.000	P46471 →
Q5E9F9	—	1.000	Q5E9F9 →
Q5R8D7	—	1.000	Q5R8D7 →
P46472	—	1.000	P46472 →
O42931	—	1.000	O42931 →
P54778	—	1.000	P54778 →
Q41365	—	1.000	Q41365 →
Q2KIW6	—	1.000	Q2KIW6 →
Q54PN7	—	1.000	Q54PN7 →
Q3T030	—	1.000	Q3T030 →
Q9SEI4	—	1.000	Q9SEI4 →
Q8SRH0	—	0.999	Q8SRH0 →
O88685	—	0.999	O88685 →
Q01939	—	0.999	Q01939 →
P33299	—	0.999	P33299 →
P78578	—	0.999	P78578 →
P62335	—	0.998	P62335 →
P62334	—	0.998	P62334 →
P0DKJ9	—	0.998	P0DKJ9 →
P0DKK0	—	0.998	P0DKK0 →
PSMC6	26S proteasome regulatory subunit 10B	0.998	landscape →
Q9SEI2	—	0.998	Q9SEI2 →
Q86JA1	—	0.998	Q86JA1 →
PSMC3	26S proteasome regulatory subunit 6A	0.997	landscape →
P46507	—	0.997	P46507 →
O42586	—	0.997	O42586 →
O76371	—	0.997	O76371 →
Q63569	—	0.997	Q63569 →